Atenolol Market - Top Companies and Manufacturers

  • Report ID: 4076
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Companies Dominating the Atenolol Landscape

    • Intas Pharmaceuticals Limited
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd
    • Danaher Corporation
    • Bio-Rad Laboratories, Inc.
    • Sysmex Corporation
    • Zydus Pharmaceuticals (USA) Inc.
    • Ipca Laboratories Limited
    • Unichem Laboratories Limited
    • AstraZeneca PLC

Browse Key Market Insights with Data Illustration:

In the News

  • Unichem Laboratories Limited obtained ANDA authorization from the United States Food and Drug Administration (USFDA) for its Atenolol and Chlorthalidone Tablets, USP 50 mg/25 mg and 100 mg/25 mg to be sold as a generic version of Alvogen Malta Operations Ltd's TENORETIC (atenolol and chlorthalidone) Tablets.

  • AstraZeneca PLC has approved the sale of the worldwide commercial rights Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril), and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma. This deal has eliminated the already sold rights in the United States and India, as well as the rights in Japan, which will be kept by AstraZeneca.


Author Credits:  Radhika Pawar


  • Report ID: 4076
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of atenolol is assessed at USD 13.33 billion.

The atenolol market size was over USD 12.23 billion in 2024 and is anticipated to cross USD 24.53 billion by 2037, witnessing more than 5.5% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of angina experiences, expansion in sedentary lifestyle, and increasing prevalence of arrhythmia will boost the market growth.

North America industry is set to hold largest revenue share of 40% by 2037, attributed to increasing prevalence of cardiac diseases, along with rising frequency of hypertension in the region.

The major players in the market are Intas Pharmaceuticals Limited, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Bio-Rad Laboratories, Inc., Sysmex Corporation, Zydus Pharmaceuticals (USA) Inc., Ipca Laboratories Limited, Unichem Laboratories Limited, AstraZeneca PLC
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample